BioDiscovery and N-of-One entered into a collaboration to provide integrated genomic analysis interpretation solutions. The partnership aims to enable clinicians to use genomic data more easily and efficiently to identify targeted therapeutic options appropriate for each specific patient as well as to better understand the molecular profile of the patient’s tumor. N-of-One and BioDiscovery also will jointly market and sell N-of-One’s interpretation solutions and content together with BioDiscovery’s genomic analysis software.
“BioDiscovery’s solutions excel at helping cytogenetic and molecular laboratories quickly identify likely actionable variants from the thousands present in typical cancer cases, with a particular emphasis on copy number variants that drive a large number of tumor types but remain difficult to interpret,” said Soheil Shams, Ph.D., CEO, BioDiscovery.“N-of-One completes the solution by taking this narrowed list and elucidating the possible therapeutic options based on an understanding of these variants in the context of the disease biology.”
“Working with BioDiscovery, developer of genomics visualization and analysis software that is already in use at many cancer centers, hospitals, and independent laboratories, we are able to strengthen the point-of-care by adding a wealth of disease-specific knowledge from the latest research findings and drug trials,” said Chris Cournoyer, CEO, at N-of-One. “This gives oncologists and treating clinicians additional insights into possible therapeutic strategies that are informed by the patient’s disease, genomic profile, available therapies and trials, and current research.”
This is N-of-One’s second collaboration this year. In February, the company announced a partnership with Appistry to jointly provide genetic sequencing data analysis and molecular interpretation services.